Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07626411 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation | PHASE3 | NOT YET_RECRUITING | 15,364 | — | — | Jul 31, 2026 | Dec 10, 2029 | Jun 4, 2026 | - | — |
| NCT07430956 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | PHASE3 | RECRUITING | 2,628 | — | — | Apr 3, 2026 | Jun 26, 2029 | May 29, 2026 | 13 | United States |
| NCT07175428 | Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | PHASE2 | RECRUITING | 1,200 | — | — | Oct 20, 2025 | Apr 21, 2027 | May 29, 2026 | 45 | United States, Canada |
Defined as the composite of International Society on Thrombosis and Haemostasis (ISTH) major bleeding, ISTH Clinically Relevant Non-Major (CRNM) bleeding, or minor bleeding
| Arm | Type | Description |
|---|---|---|
| REGN7508 + Placebo | EXPERIMENTAL | - |
| Apixaban + Placebo | ACTIVE_COMPARATOR | - |
| REGN7508 | EXPERIMENTAL | - |
| REGN9933 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Apixaban | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| REGN7508 | DRUG | Administered per the protocol |
| Apixaban | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
| REGN9933 | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Has AF or flutter (paroxysmal or persistent), not considered to be secondary to a reversible cause, and an indication for indefinite anticoagulation treatment as described in the protocol 2. Meets one of the following: 1. CHA2DS2-VA \[C: Congestive heart failure; H: H...